CRISPR/Cas9-mediated genomic deletion of the beta-1, 4 nacetylgalactosaminyltransferase 1 gene in murine P19 embryonal carcinoma cells results in low sensitivity to botulinum neurotoxin type C

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Tsukamoto, Kentaro ^a   Ozeki, Chikako ^a   Kohda, Tomoko ^b   Tsuji, Takao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,4 N ACETYLGALACTOSAMINYLTRANSFERASE 1; BOTULINUM TOXIN; BOTULINUM TOXIN C; GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GT1B; N ACETYLGALACTOSAMINYLTRANSFERASE; UNCLASSIFIED DRUG; BETA-D-GALACTOSIDE ALPHA 2-6-SIALYLTRANSFERASE; BOTULINUM TOXIN TYPE C; GANGLIOSIDE, GD1A; GANGLIOSIDE, GD1B; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; SIALYLTRANSFERASE; SMALL INTERFERING RNA; TRISIALOGANGLIOSIDE GT1;

ANIMAL CELL; ARTICLE; BETA 1, 4 N ACETYLGALACTOSAMINYLTRANSFERASE 1 GENE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DNA MODIFICATION; EMBRYONAL CARCINOMA CELL LINE; GENE DELETION; GENOME ANALYSIS; MOUSE; NERVE CELL; NONHUMAN; P19 CELL; SENSITIVITY ANALYSIS; TOXICITY TESTING; TOXIN ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; EMBRYONAL CARCINOMA STEM CELL; GENETICS; METABOLISM; PROTEIN DEGRADATION; RNA INTERFERENCE; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

ANIMALS; BOTULINUM TOXINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; EMBRYONAL CARCINOMA STEM CELLS; GANGLIOSIDES; MICE; MICROSCOPY, CONFOCAL; N-ACETYLGALACTOSAMINYLTRANSFERASES; PROTEOLYSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIALYLTRANSFERASES; SURFACE PLASMON RESONANCE;

EID: 84941287149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132363     Document Type: Article

References (25)

1. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009; 109: 1584-1595. doi: 10.1111/j.1471-4159.2009.06093.x PMID: 19457120
2. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986; 26: 427-453. PMID: 3521461
3. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 1993; 12: 4821-4828. PMID: 7901002
4. Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 1986; 35: 2630-2636.
5. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010; 79: 591-617. doi: 10.1146/annurev.biochem.051908.125345 PMID: 20233039
6. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell. 2008; 19: 5226-5237. doi: 10.1091/ mbc.E08-07-0765 PMID: 18815274
7. Dong M, Tepp WH, Liu H, Johnson EA, Chapman ER. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol. 2007; 179: 1511-1522. PMID: 18158333
8. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Chapman ER. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312: 592-596. PMID: 16543415
9. Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry. 2009; 48: 5631-5641. doi: 10.1021/bi9002138 PMID: 19476346
10. Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, Takahashi M, et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem. 1994; 269: 10498-10503. PMID: 8144634
11. Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, et al. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci. 2012; 125: 3233-3242. doi: 10.1242/jcs.103564 PMID: 22454523
12. Tsukamoto K, Kohda T, Mukamoto M, Takeuchi K, Ihara H, Saito M, et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem. 2005; 280: 35164-35171. PMID: 16115873
13. Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry. J Biol Chem. 2012; 287: 40806-40816. doi: 10. 1074/jbc.M112.404244 PMID: 23027864
14. Strotmeier J, Gu S, Jutzi S, Mahrhold S, Zhou J, Pich A, et al. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol Microbiol. 2011; 81: 143-156. doi: 10.1111/j.1365-2958.2011.07682.x PMID: 21542861
15. Tsukamoto K, Arimitsu H, Ochi S, Nakamura K, Tanaka Y, Nuemket N, et al. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins. Microbiol Immunol. 2012; 56: 664-672. doi: 10.1111/j.1348-0421.2012.00490.x PMID: 22738015
16. Soprano DR, Teets BW, Soprano KJ. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitam Horm. 2007; 75: 69-95. PMID: 17368312
17. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNAguided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2012; 154: 1380-1389.
18. Kurazono H, Shimozawa K, Hosokawa M, Sakaguchi G. Procedures for large-scale production and purification of Clostridium botulinum C1 toxin for preparation of toxoid. FEMS Microbiol Lett. 1985; 30: 47-51.
19. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog. 1998; 25: 91-99. PMID: 9712688
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25: 402-408. PMID: 11846609
21. Nakamura K, Kohda T, Shibata Y, Tsukamoto K, Arimitsu H, Hayashi M, et al. Unique biological activity of botulinum D/C mosaic neurotoxin in murine species. Infect Immun. 2012; 80: 2886-2893. doi: 10. 1128/IAI.00302-12 PMID: 22665374
22. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. 2013; 31: 233-239. doi: 10.1038/nbt.2508 PMID: 23360965
23. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013; 31: 822-826. doi: 10. 1038/nbt.2623 PMID: 23792628
24. Nakamura K, Kohda T, Umeda K, Yamamoto H, Mukamoto M, Kozaki S. Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan. Vet Microbiol. 2010; 140: 147-154. doi: 10.1016/j.vetmic.2009.07.023 PMID: 19720474
25. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNAguided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337: 816-821. doi: 10.1126/ science.1225829 PMID: 22745249